Open Up a World
WITH FEWER EXACERBATIONS
DUPIXENT demonstrated severe exacerbation reduction up to ~3 years.
Severe exacerbations through Week 24
reduction in severe exacerbationsa through Week 24
with DUPIXENT 300 mg Q2W + SOC (n=64) vs placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (baseline blood EOS ≥300 cells/µL, DRI12544, secondary endpoint)1
QUEST primary endpoint results (ITT population)
- 48% reduction in severe exacerbations at Week 52 in patients with no biomarker requirement with DUPIXENT 200 mg Q2W + SOC (n=631) vs placebo + SOC (n=317) (rate ratio: 0.52 [95% CI: 0.41, 0.66])1
- 46% reduction in severe exacerbations at Week 52 in patients with no biomarker requirement with DUPIXENT 300 mg Q2W + SOC (n=633) vs placebo + SOC (n=321) (rate ratio: 0.54 [95% CI: 0.43, 0.68])1
aSevere exacerbations were defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or hospitalization or ED visit due to asthma that required systemic corticosteroids.1
Severe exacerbations through Weeks 48 to 96
of patients did not have an exacerbation requiring hospitalization or ED visit
- Patients rolled over from DRI12544 and QUEST treated with DUPIXENT 300 mg Q2W + SOC (n=2062) during the second and third years in the OLE period (TRAVERSE OLE study, secondary endpoint)2,b,c
exacerbations in 89% of patients from QUEST in Year 3
(Weeks 48-96) when treated with DUPIXENT 200 mg/300 mg Q2W + SOC (n=816) for 52 weeks in QUEST and continued with DUPIXENT 300 mg Q2W + SOC in the OLE period (TRAVERSE OLE study, other endpoint)2
- 79.5% of patients rolled over from DRI12544 (n=396) experienced 0 exacerbations during Weeks 48-962
- 74% of patients rolled over from DRI12544 and QUEST (n=2062) experienced 0 exacerbations over ~3 years of treatment with DUPIXENT2
Results are descriptive. Definitive conclusions cannot be made.
Data were not multiplicity controlled and there are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.
bAnalysis includes DRI12544 and QUEST patients enrolled in TRAVERSE.2
cOf the 542 patients who experienced at least 1 severe asthma exacerbation, 66 (3.2% of the overall study population) had an exacerbation that required hospitalization or ED visit during the TRAVERSE study period (unadjusted annualized event rate of 0.027).2
DUPIXENT reduced severe exacerbations in patients with elevated EOS (≥150 cells/μL) and elevated EOS + allergic asthma2
PATIENTS WITH ELEVATED EOS (QUEST, prespecified subgroup analyses)
Reductions in severe exacerbations when added to SOC. No statistically
significant differences were observed during the 52-week treatment period in patients with
baseline blood EOS <150 cells/μL taking DUPIXENT 200 mg Q2W or 300 mg Q2W + SOC and in the
≥150 to <300 cells/μL eosinophil subgroup treated with DUPIXENT 200 mg Q2W + SOC vs
matching placebo + SOC.1,2
DUPIXENT trials enrolled patients with eosinophil levels up to 1500
cells/μL.1
dSecondary endpoint.2
PATIENTS WITH ELEVATED EOS + ALLERGIC ASTHMA (QUEST, post hoc analyses)
Results are descriptive. Definitive conclusions cannot be made as this was
a post-hoc analysis. There are limitations on sample size and data
were
not multiplicity controlled.
Allergic asthma was defined as total serum IgE ≥30 IU/mL + ≥1 positive perennial-aeroallergen–specific IgE ≥0.35 kU/L at baseline.3
(POST HOC ANALYSIS)
Severe exacerbations through Week 52
reduction in severe exacerbationse through Week 52
with DUPIXENT 300 mg Q2W + SOC (n=129) vs placebo + SOC (n=61) (rate ratio:
0.29 [95% CI:
0.17, 0.51]) (baseline blood EOS ≥300
cells/μL, QUEST, post hoc
analysis)2,4,5
- 73% reduction in severe exacerbations through Week 52 with DUPIXENT 200
mg Q2W + SOC (n=134) vs placebo + SOC (n=68) (rate
ratio: 0.27 [95% CI: 0.15, 0.48]) (baseline blood EOS ≥300 cells/μL, QUEST, post hoc analysis)2,4,5
Results are descriptive. Definitive conclusions cannot be made as this was a post-hoc
analysis. There are limitations on sample size and data
were not
multiplicity controlled.
eSevere exacerbations were defined as deterioration
of asthma requiring the use of
systemic corticosteroids for at least 3 days or hospitalization
or ED visit due to asthma that
required systemic corticosteroids.1
Severe exacerbations through Week 96
exacerbations in 70% of patients from QUEST in Year 3
(Week 96) when treated with
DUPIXENT 300 mg Q2W + SOC
(n=215) for 52 weeks
in QUEST
and
continued with DUPIXENT
300
mg Q2W + SOC in the OLE
period
(baseline blood EOS ≥300
cells/μL,
TRAVERSE OLE study,
post hoc
analysis)2,4
Results are descriptive. Definitive conclusions cannot be made as this was a post hoc analysis of open-label extension data.
Data were not multiplicity controlled and there are limitations associated with
open-label study design, including lack of comparator arm, decreasing sample size, and
potential continued involvement of responders and attrition of
nonresponders.
Patients with higher short-acting beta agonist use (3+ canisters/
year)
were more likely to
experience 1+ severe exacerbation requiring an
HCP visit or
hospitalization6,f
fBased on observational analyses of SABA use IN Asthma
(SABINA)
datasets involving patients from Europe and North
America.
Consider DUPIXENT sooner
for your appropriate
asthma
patients on
medium ICS dose + one
or more controller
ED, emergency department;
EOS, eosinophils; ICS,
inhaled corticosteroid; ITT, intention-to-treat; OLE,
open‑label
extension; Q2W, once every 2 weeks; SOC,
standard of care.
Consider DUPIXENT sooner for your appropriate asthma patients on medium ICS dose + one or more controller
ED, emergency department; EOS, eosinophils; ICS, inhaled corticosteroid; ITT, intention-to-treat; OLE, open‑label extension; Q2W, once every 2 weeks; SOC, standard of care.
Explore the SAFETY
DATA AND STUDY DESIGNS
Dosage and Administration
options for patients on DUPIXENT.